When a new drug goes in front of the FDA for consideration, a lot of moving pieces must be in place for a successful review—manufacturing standards included. That didn’t happen for Sanofi, which is pressing pause on a rare disease candidate after the FDA found issues at a contract manufacturer’s plant.
The FDA blasted a third-party manufacturer of Sanofi’s rare blood disease drug sutimlimab in a complete response letter, citing “certain deficiencies” at the contractor’s site, the French drugmaker said Friday.
A Sanofi spokeswoman declined to specify who the manufacturer cited in the FDA’s letter was or what the nature of the deficiencies were.
Whitepaper
The Rise of HPAPI Molecules – Trends in Highly Potent API Manufacturing
Highly potent active pharmaceutical ingredients are increasing in pharma pipelines. Lonza offers all HPAPI-related expertise to support your product development from concept to commercial use in an integrated manner.
With its application on hold, Sanofi said it would work with its manufacturer and the FDA to resolve the issues in a “timely manner.” The drugmaker didn’t say how quickly it expected to turn around a new application.
The untimely feedback from the FDA dims C1 inhibitor sutimlimab’s chances in cold agglutinin disease (CAD), a rare blood disease characterized by anemia, fatigue and other symptoms.
twisted family secrets full movie limpiando culo snigdha sinha video anyxvideos.com sex slave full video view here ksb besaba com katrina reyal sex garden on house wife rape 1st sex young xnxx-br.com bd bdsexvideo sasur bhou sex romance bluepornsex video xxx vide0 gan czech teen swallow money گایدن افقانی anushka sharma ki video vdeo xxx japaeb fetishwife clare